Equities

Futura Medical PLC

Futura Medical PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)47.40
  • Today's Change0.40 / 0.85%
  • Shares traded261.55k
  • 1 Year change+43.64%
  • Beta2.8820
Data delayed at least 20 minutes, as of Dec 09 2022 16:21 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is focused on developing a portfolio of products based on its transdermal DermaSys technology. Its patented transdermal DermaSys technology provides rapid and targeted local delivery of medical treatments via the skin. The Company is engaged in developing a portfolio of products for therapeutic areas, such as sexual health, including erectile dysfunction, and pain relief. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. TPR100 is a topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism.

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-5.87m
  • Incorporated2001
  • Employees11.00
  • Location
    Futura Medical PLCUnit 40Surrey Technology Centre, Occam RoadGUILDFORD GU2 7YGUnited KingdomGBR
  • Phone+44 148 368 5670
  • Fax+44 148 368 5671
  • Websitehttp://www.futuramedical.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Arecor Therapeutics PLC1.39m-7.43m76.55m37.00--4.77--55.03-0.3249-0.32490.06040.52370.0681--0.684137,594.05-36.37---41.23-------534.19--6.24-535.050.0115---31.79---124.13------
Eco Animal Health Group Plc78.58m779.00k78.90m221.00102.190.942124.831.000.01140.01141.161.240.66951.522.93355,565.601.097.781.5310.0642.5346.981.6310.422.14--0.018353.51-22.176.00-109.35---18.83--
Open Orphan PLC32.93m-1.06m79.18m218.00--3.8126.962.40-0.0016-0.00160.04910.0310.7473--2.95151,045.90-2.41-21.58-4.85-39.82-----3.23-25.221.162.530.0981--78.9320.2399.31--62.75--
Allergy Therapeutics plc72.77m-13.78m81.49m601.00--2.04--1.12-0.022-0.0220.10940.05870.90022.098.72---17.04-2.20-21.93-2.8768.0373.25-18.93-2.091.74-29.720.2152---13.712.56-577.34--13.67--
4Basebio PLC311.00k-4.02m86.22m----9.09--277.24-0.326-0.3260.02530.77040.02250.54623.03---29.00---31.54--78.14---1,291.00--4.16-45.150.1341---26.84---349.93------
e-Therapeutics plc295.00k-9.09m122.24m32.00--4.44--414.39-0.0188-0.01880.00060.04740.0099--1.419,218.75-30.62-37.71-31.65-40.40100.00100.00-3,082.71-1,812.91----0.0199--50.47---119.06--42.31--
Animalcare Group Plc73.19m2.00m132.20m211.0066.751.6813.341.810.0330.0331.211.310.61992.806.09346,867.301.70--2.02--53.96--2.74--0.99926.920.1474--5.01---132.91------
Futura Medical plc.0.00-5.87m136.53m11.00--18.46-----0.0204-0.02040.000.02570.00----0.00-52.23-65.78-57.68-86.83-------6,607.25----0.00-------105.85--123.78--
Niox Group PLC28.80m13.20m157.76m128.0012.812.159.015.480.02940.03050.06350.17450.3173.003.97225,000.0014.53-11.6916.73-13.9969.7976.1945.83-81.992.00--0.0201--16.743.85108.58---22.16--
Bioventix PLC11.72m7.67m192.22m17.0025.2916.2624.5916.401.461.462.232.270.90061.792.38--58.9853.9264.5957.7593.9492.5565.4864.969.07----76.927.2210.0914.019.29-11.5319.83
Redx Pharma PLC16.29m-18.62m204.30m71.00--31.21--12.54-0.0679-0.06790.05940.01950.38--46.40229,394.40-43.45-40.30-63.41-66.57-----114.35-85.78---10.980.7683--76.52---134.19--11.17--
Data as of Dec 09 2022. Currency figures normalised to Futura Medical PLC's reporting currency: UK Pound GBX

Institutional shareholders

70.97%Per cent of shares held by top holders
HolderShares% Held
Lombard Odier Asset Management (Europe) Ltd.as of 06 Jun 202277.57m26.95%
UBS Asset Management (UK) Ltd.as of 02 Oct 202233.46m11.63%
Hargreaves Lansdown Stockbrokers Ltd.as of 02 Oct 202224.55m8.53%
Janus Henderson Investors UK Ltd.as of 02 Oct 202221.82m7.58%
Lombard Odier Asset Management (USA) Corp.as of 02 Oct 202210.71m3.72%
Chelverton Asset Management Ltd.as of 30 Jun 20228.65m3.01%
Hargreaves Lansdown Asset Management Ltd.as of 02 Oct 20228.53m2.96%
Atlantis Investment Management Ltd. /Hong Kong/as of 21 Apr 20217.94m2.76%
Unicorn Asset Management Ltd.as of 30 Nov 20225.75m2.00%
Northern Trust Global Investments Ltd. (Securities Lending)as of 02 Oct 20225.27m1.83%
More ▼
Data from 31 Mar 2022 - 30 Nov 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.